Catalysing Success in Life Sciences

OBN is a not-for-profit membership network that catalyses growth for the life sciences industry. Whether you’re an emerging entrepreneur, R&D SME, investor, analyst, pharma company, science park, TTO or technology / professional services organisation, we are here to give you opportunities to meet, learn, and grow. Read more about how we can help you to:

Create Connections Secure Investment Save Time & Money Join OBN

Patron

Join us at the next OBN event

Make connections and keep up to date with the latest life sciences industry innovations. View upcoming OBN and Member events.

20 Jan

8:30am – 6:30pm

etc.venues County Hall

BioSeed 2025

01 Apr – 02 Apr

8:30am – 5:30pm

Convene

BioTrinity 2025

We pride ourselves on supporting our members to catalyse their success.

We do this by keeping the life sciences community connected and informed, making us an essential partner.

But don’t take our word for it, here is what our members and partners say.

“At Oxford Endovascular we feel that OBN’s well informed team is really invested in our journey, supporting us as the business develops.”

Mike Karim Oxford Endovascular , CEO

“Through OBN we can make valuable connections with potential customers, keeping them informed about Biosynth’s products and services. Other advantages to being an OBN member include discounted rates for events and conference attendance.”

Adrian Hery Barranco Biosynth, Marketing & Business Development Officer

“I’ve met a number of amazing people through OBN, who are all so open to sharing their experience and helping to support emerging biotechs. I’d encourage everyone to join in, whether a seasoned industry insider, an emerging biotech with exciting science, or a sponsor aiming to build their brand and support new biotech – OBN is great!”

Nick Pumphrey Etcembly, CSO

Latest News

16/10/24 General

IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strate…

16/10/24 General

Coulter Partners Top hires for VC & PE portfolio companies Q3-2024

15/10/24 General

Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

15/10/24 General

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug

15/10/24 General

Oxford North appoints new managing director